Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443103 · ClinicalTrials.gov registry record · NA
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
A NA study, sponsored by Kathy Miller.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02443103: Clinical Trial NA study, sponsored by Kathy Miller.
NCT02443103 is a NA study that was terminated before completion, run by Kathy Miller. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02443103, a NA study, was terminated before completion, sponsored by Kathy Miller.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound.
Primary Outcome
Number of patients who had blood specimens taken to collect and evaluate markers of bone formation and bone resorption. Note - due to poor accrual and early closure, bone marker data was not collected.
Interventions
- DRUG Guanabenz acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2016-06-08 |
| Phase | NA |
Why NCT02443103 stopped before completion
NCT02443103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Guanabenz acetate is the first listed.
NCT02443103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02443103 about?
NCT02443103 is a clinical study titled "Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis". This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound.
What is the current status of trial NCT02443103?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2015-05-07. Estimated completion is 2016-06-08.
What interventions are being tested in trial NCT02443103?
The interventions under investigation include: Guanabenz acetate (DRUG).
Who is sponsoring clinical trial NCT02443103?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02443103's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI